16th Annual BioPharma & Healthcare Summit, Friday, June 24, 2022 - Virtual Meeting

Chair and Master of Ceremonies (Emcee) - Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals
16th annual BioPharma & Healthcare Summit

Welcome address: Karun Rishi, President, USAIC

Opening comments: Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals

Moving Closer to Cure for More Cancer Patients

Panelists:
Dr. Christine Ward, Vice President, Head of Oncology and Cell Therapy, Takeda Pharmaceuticals
Dr. Eric Rubin, Senior Vice President, Therapeutic Area Head Oncology, Early Development, Merck Research Labs
Dr. Samarth Kulkarni, Chief Executive Officer, CRISPR Therapeutics
Dr. Sam Waksal, Chairman and Chief Executive Officer, Equilibre Biopharmaceuticals
Dr. Todd Golub, Director and Founding Core Member, Broad Institute of MIT & Harvard
Moderator:
Dr. Alise Reicin, Chief Executive Officer, Tectonic Therapeutic

Fireside Chat
Alex Gorsky, Executive Chairman, Johnson & Johnson
Moderator:
Christopher Viehbacher, Founding Partner, Gurnet Point Capital

Clinical Trials Landscape in India

Panelists:
Dr. Cynthia Verst, President, Design & Delivery Innovation for Research and Development Solutions, IQVIA
Dr. Kush Parmar, Managing Partner, 5AM Ventures
Dr. Naresh Trehan, Chairman, Medanta
Peter Ronco, Head of Global Development, Janssen Research and Development, Johnson & Johnson
Dr. Vinod Paul, Member, National Institution for Transforming India, the NITI Aayog
Moderator:
Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals

Digital & Data Science Panel

Panelists:
Daphne Zohar, Founder & Chief Executive Officer, PureTech Health
Dr. Karen Akinsanya, President of Research and Development, Therapeutics, Schrodinger
Dr. Regina Barzilay, Professor of AI and Health, Massachusetts Institute of Technology
Sastry Chilukuri, Co-Chief Executive Officer, Medidata
Dr. Vipin Gopal, Chief Data & Analytics Officer, Eli Lilly
Moderator:
Chris Benko, Co-Founder and Chief Executive Officer, Koneksa Health

Pandemics: Where does the world go from here

Panelists:
Dr. Larry Tabak, Acting Director, National Institutes of Health (NIH)
Dr. John Mascola, Chief Scientific Officer, ModeX Therapeutics
Dr. Julie Gerberding, Chief Executive Officer, Foundation for the NIH (FNIH)
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon
Moderator:
Dr. Elias Zerhouni, Professor Emeritus, Johns Hopkins University

Industry & Investment Outlook Panel

Panelists:
Christopher Viehbacher, Founding Partner, Gurnet Point Capital
Hari Bhartia, Founder & Co-Chairman, Jubilant Bhartia Group
Rajiv Kaul, Portfolio Manager, Fidelity Investments
Dr. Stelios Papadopoulos, Chairman of the Board, Biogen
Moderator:
Jennifer Fox, Chief Financial Officer, Nuvation Bio

Rethinking Rare: Resolutions for reinvention in a genomic age

Panelists:
Dr. Alfred Sandrock, Chief Executive Officer, Voyager Therapeutics
Charlene Son Rigby, Chief Executive Officer, RARE-X
Paula Soteropoulos, Chairman of the Board, Ensoma
Dr. Philip Larsen, Global Head of Research, Bayer Pharma
Max Bronstein, Assistant Director for Health Innovation, White House Office of Science & Technology Policy
Moderator:
Dr. Timothy Yu, Associate Professor in Pediatrics, Harvard Medical School

Research and Development Strategies & Trends Panel

Panelists:
Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals
Dr. David Reese, Executive Vice President, Research and Development, Amgen
Dr. John Reed, Global Head of Research and Development, Sanofi
Dr. Mathai Mammen, Executive Vice President, Pharmaceuticals, Research and Development, Johnson & Johnson
Moderator: 
Dr. Martin Mackay, Co-Founder, Rallybio

Closing Remarks and Wrap Up

Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals
Advisory Board Members and Speakers

15th Annual BioPharma & Healthcare Summit, Tuesday, June 22, 2021 - Virtual Meeting

Chair and Master of Ceremonies (Emcee)– Dr. Andrew Plump, President of R&D, Takeda Pharmaceuticals
Summit Theme: "From N of One to N of a Billion"

Welcome address: Karun Rishi, President, USAIC [ Watch Video ]

Opening comments: Dr Andrew Plump, President of R&D, Takeda Pharmaceuticals [ Watch Video ]

Fireside Chat: Dr. Albert Bourla, Chairman & CEO, Pfizer [ Watch Video ]
Moderator: Dr. Stelios Papadopoulos, Chairman of the Board, Biogen

India Innovation Panel [ Watch Video ]

Panelists: Amitabh Kant, Chief Executive Officer, National Institution for Transforming India, Dilip Shanghvi, Managing Director, Sun Pharmaceutical Industries Limited, Prof. K. Vijay Raghavan, Principal Scientific Advisor, Government of India, Dr. Naresh Trehan, Chairman, Medanta Hospital
Moderator: Sanat Chattopadhyay, President- Merck Manufacturing Division, Merck & Co.

Rare Disease Panel [ Watch Video ]

Panelists: Dr. David Meeker, Chairman & CEO, Rhythm Pharmaceuticals, Dr. Frank Bennett, Chief Scientific Officer, Ionis Pharmaceuticals, Dr. John Orloff, Head of Research & Development, Alexion, Dr. Katherine High, President - Therapeutics, AskBio, Majid Jafar, Co-Founder, Loulou Foundation
Moderator: Dr. Alfred Sandrock, Head of Research and Development, Biogen

Fireside Chat: Robert Bradway, Chairman & CEO, Amgen [ Watch Video ]
Moderator: Kiran Mazumdar-Shaw, Executive Chairperson, Biocon

Fireside Chat: Dr. Francis Collins, Director, National Institutes of Health, Dr. Margaret Hamburg, Former Commissioner, U.S. Food and Drug Administration [ Watch Video ]
Moderator: Dr. Elias Zerhouni, Professor Emeritus, Johns Hopkins University

Oncology Panel [ Watch Video ]

Panelists: Dr. Bruce Chabner, Director of Clinical Research, Massachusetts General Hospital Cancer Center, Dr. Carrie Brownstein, Chief Medical Officer, Cellectis, Dr. Philip Larsen, Global Head of Research, Bayer AG, Dr. Sam Waksal, Founder, MeiraGTx, Vivek Ramaswamy, Founder & Executive Chairman, Roivant Sciences
Moderator: Dr. Alise Reicin, Chief Executive Officer, Tectonic Therapeutic

Industry & Investment Outlook Panel [ Watch Video ]

Panelists: Christopher Viehbacher, Managing Partner, Gurnet Point Capital, Dr. Peter Orszag, Chief Executive Officer - Financial Advisory, Lazard Freres, Rajiv Kaul, Portfolio Manager, Fidelity Investments, Dr. Stelios Papadopoulos, Chairman, Biogen
Moderator: Daphne Zohar, Co-Founder and Chief Executive Officer, PureTech Health

Fireside Chat: Dr. Janet Woodcock, Acting Commissioner, U.S. Food and Drug Administration [ Watch Video ]
Moderator: Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

R&D Strategies & Trends Panel [ Watch Video ]

Panelists: Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals, Dr. David Reese, Executive Vice President, Research and Development, Amgen, Dr. John Reed, Global Head of R&D, Sanofi, Dr. Mathai Mammen, Global Head of Janssen R&D, Johnson & Johnson
Moderator: Dr. Martin Mackay, Co-Founder, Rallybio

Digital & Data Science Panel [ Watch Video ]

Panelists: Craig Kennedy, Senior Vice President, Merck & Co., Dr. Daphne Koller, Founder & CEO, insitro, Dr. Karen Akinsanya, Chief Biomedical Scientist, Schrödinger, Dr. Najat Khan, Chief Data Science Officer, Janssen Research & Development, Dr. Robert Califf, Head of Clinical Policy & Strategy, Verily & Google Health
Moderator: Sastry Chilukuri, President, Acorn AI- Medidata

Closing Remarks: Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals [ Watch Video ]

14th Annual BioPharma & Healthcare Summit, September 4, 2020 - Virtual Meeting

Chair and Master of Ceremonies- Dr. Andrew Plump, President of Research and Development, Takeda Pharmaceuticals

Welcome address: Karun Rishi, President, USAIC

Panel Discussion- COVID-19: Where are we now? Where are we going?

Panelists: Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health; Dr. George Yancopoulos, Co-Founder, President & CSO, Regeneron; Kiran Mazumdar-Shaw, Executive Chairperson, Biocon; Dr. Rajeev Venkayya, President-Global Vaccines, Takeda; Dr. Richard Hatchett, CEO, Coalition for Epidemic Preparedness Innovations (CEPI)
Moderator: Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

India Regulatory update: Dr. Mandeep Bhandari, Joint Secretary, Ministry of Health & Family Welfare, India; Dr. V G Somani, Drug Controller General of India, Central Drug Control Organization
Moderator: Muna Bhanji, Senior Vice President,  Merck & Co.

Fireside Chat: Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co.
Moderator: Dr. Stelios Papadopoulos, Chairman of the Board, Biogen

India Innovation Landscape

Panelists: Amitabh Kant, Chief Executive Officer, National Institution for Transforming India (NITI); Hari Bhartia, Founder & C o-Chairman, Jubilant Bhartia Group; Dr. K. Vijay Raghavan, Principal Scientific Advisor, Government of India; Dr. Naresh Trehan, Chairman, Medanta - the Medicity
Moderator: Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co.

Panel Discussion- Oncology: A never ending tunnel?

Panelists: Dr. Alise Reicin, Former President, Global Clinical Development, Celgene; Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute; Dr. Philip Larsen, Global Head of Research, Bayer AG; Rehan Verjee, President, EMD Serono
Moderator: Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

Panel Discussion- Industry & Investment Outlook

Panelists: Christopher Viehbacher, Managing Partner, Gurnet Point Capital; Daphne Zohar, Founder & CEO, PureTech Health; Dr. Elias Zerhouni, Professor Emeritus, Johns Hopkins University; Dr. Stelios Papadopoulos, Chairman, Biogen
Moderator: Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals

Panel Discussion- Rare Diseases: No longer forgotten; but more to be achieved

Panelists: Dr. Alfred Sandrock, Executive Vice President, Research & Development, Biogen; Dr. Daniel Curran, Head of the Rare Diseases Therapeutic Area Unit, Takeda; Dr. David Meeker, Chairman & CEO , Rhythm Pharmaceuticals; Dr. John Orloff, Head of Research & Development, Alexion; Matt    Wilsey, Co-Founder & Chairman, Grace Science Foundation
Moderator: Dr. Steve Uden, Co-Founder, Rallybio

Fireside Chat; Dr. Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals
Moderator: Dr. Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical Companies of J&J

Panel Discussion- Digital & Data Science in Healthcare: Pragmatic Insights from the Real-World

Panelists: Dr. Anne Heatherington, Head of Data Sciences Institute, Takeda Pharmaceuticals; Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Merck & Co.; Dr. Maya Said, Chief Executive Officer, Outcomes4Me; Dr. Najat Khan, Chief Operating Officer, Janssen R&D Data Sciences, Johnson & Johnson; Nina Kjellson, General Partner, Canaan
Moderator: Sastry Chilukuri, President, Acorn AI- Medidata

Panel Discussion- R&D Strategies and Trends: Innovation- The Big I

Panelists: Dr. Andrew Plump, President of Research & Development, Takeda Pharmaceuticals; Dr. David Reese, Executive Vice President, Research and Development, Amgen; Dr. Hal Barron, Chief Scientific Officer and President, R&D, GlaxoSmithKline; Dr. Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical Companies of J&J
Moderator: Dr. Martin Mackay, Co-Founder, Rallybio

13th annual BioPharma & Healthcare Summit, Marriott Cambridge, Massachusetts, USA May 9, 2019

Master of Ceremonies- Dr Andrew Plump, President R&D, Takeda Pharmaceuticals
Welcome address: Karun Rishi, President, USA India Chamber of Commerce

Fireside Chat

Mark Abdoo, Acting Deputy Commissioner, U.S. Food and Drug Administration
Dr. Eswara Reddy, Drug Controller General of India, Central Drug Control Organization
Moderator: Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co.

Presentation on CAR (chimeric antigen receptor) T-cell Therapies

Dr. Carl June, Director of Translational Research, Abramson Cancer Center University of Pennsylvania
Moderator: Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

Panel Discussion: Oncology – The Emperor of BioPharma Development

Panelists: Dr. Arjun Surya, Co-Founder & CSO, Curadev Pharma; Dr. Christopher Arendt, Head- Immunology Unit and Oncology DDU, Takeda; Dr. David Meeker, President & CEO, KSQ Therapeutics; Dr. Marcela Maus, Director of Cellular Immunotherapy, MGH Cancer Center; Dr. Sanjiv Patel, President & Chief Executive Officer, Relay Therapeutics
Moderator: Dr. Christiana Bardon, Managing Director, MPM Capital

Panel Discussion: Future of Clinical Trials and Drug Development
Panelists: Dr. Alise Reicin, President, Global Clinical Development, Celgene; Dr. Bruce Chabner, Director of Clinical Research, Mass General Hospital Cancer Center; Dr. Mace Rothenberg, Chief Medical Officer, Pfizer; Dr. Michael Rosenblatt, Chief Medical Officer, Flagship Pioneering; Dr. Rob Scott, Chief Medical Officer, Abbvie
Moderator: Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

Panel Discussion: Manufacturing in the Future

Panelists: Hari Bhartia, Founder and Co-Chairman, Jubilant Bhartia Group; Mark Abdoo, Acting Deputy Commissioner, U.S. Food and Drug Administration; Dr. Paul McKenzie, Executive Vice President, Pharma Operations & Technology, Biogen; Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co.; Vinay Ranade, Chief Executive Officer, Reliance Life Sciences
Moderator: Professor N. Venkat Venkatraman, Boston University Questrom School of Business

Panel Discussion: One in a million - Emerging trends in Rare Diseases

Panelists: Dr. Daniel Curran, Head of the Rare Diseases Therapeutic Area Unit, Takeda; David Lucchino, Co-Founder and CEO, Frequency Therapeutics; Dr. Dhaval Patel, Executive Vice President  and Chief Scientific Officer, UCB; Dr. James Wilson, Director- Gene Therapy Program, University of Pennsylvania; Dr. Timothy Yu, Assistant Professor in Paediatrics, Harvard Medical School
Moderator: Dr. Samarth Kulkarni, Chief Executive Officer, CRISPR Therapeutics

Fireside Chat: Value and Access – The ongoing debate
Christopher Viehbacher, Managing Partner, Gurnet Point Capital; Dr. John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals; Dr. Stelios Papadopoulos, Chairman, Biogen
Moderator: Dr. Andrew Plump, President R&D, Takeda Pharmaceuticals

India update on Clinical Trial Regulations
Arun Singhal, Additional Secretary, Ministry of Health & Family Welfare, India; Dr. Eswara Reddy, Drug Controller General of India, Central Drug Control Organization
Moderator: Karun Rishi, President, USA-India Chamber of Commerce

Panel Discussion: Research and Development Strategies and Trends

Panelists: Dr. Andrew Plump, President R&D, Takeda Pharmaceuticals; Dr. James Bradner, President, Novartis Institutes for BioMedical Research; Dr. Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical Companies of J&J
Moderator: Dr. Martin Mackay, Co-Founder, Rallybio

Strategy Sessions Co-Chairs:

External Research and Development Strategy Session

Manni Kantipudi, Chief Executive Officer, GVK BIO
Dr. Raj Manchanda, Portfolio Leader, Gates Medical Research Institute
Dr. Ulrich Stilz, Vice President, Novo Nordisk
Dr. Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals

Technology Platforms Strategy Session
Sastry Chilukuri, Executive Vice President, Medidata
Colin Hill, Chairman & CEO, GNS Healthcare
Dr. Sridaran Natesan, Vice President, Sanofi
Dr. John Reynders, Vice President, Alexion Pharmaceuticals

12th annual BioPharma & Healthcare Summit, Marriott Cambridge, Massachusetts, USA May 8, 2018

Master of Ceremonies- Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals
Welcome address: Karun Rishi, President, USA-India Chamber of Commerce

Panel Discussion: Industry-Academic Research Partnerships

Panelists: Dr. Chas Bountra, Chief Scientist, University of Oxford; Dr. Jim Glasheen, Executive Vice Chancellor, UMass Medical School; Dr. Jonathan Epstein, Executive Vice Dean & Chief Scientific Officer, Perelman School of Medicine, University of Pennsylvania; Dr. Nirmal Kumar Ganguly, President, Apollo Hospitals Educational & Research Foundation; Dr. Sridaran Natesan, Vice President, Head - Strategic Initiatives & Scientific Relations, R&D, Sanofi
Moderator: Juan Harrison, Vice President, Head of Strategic Academic Alliances, Takeda Pharmaceuticals

Panel Discussion: Neuro Diseases                                                                           

Panelists: Dr. Alfred Sandrock, Executive Vice President & Chief Medical Officer, Biogen; Dr. David Goldstein, Director, Institute for Genomic Medicine, Columbia University Medical Center; Dr. Maurizio Fava, Associate Dean, Clinical & Translational Research, Harvard Medical; Dr. Meeta Chatterjee, Head, Business Strategy & Ops, BD&L, Merck Research Labs; Dr. Steven Paul, President and CEO, Voyager Therapeutics
Moderator: Dr. Steve Uden, Co-Founder, Rallybio

Panel Discussion: Oncology

Panelists: Dr. Bruce Chabner, Director of Clinical Research, Mass General Hospital Cancer Center; Dr. Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals; Dr. Philip Rowlands, Head of the Oncology TAU, Takeda Pharmaceuticals; Dr. Victoria Richon, President & CEO, Ribon Therapeutics; Dr. Rakesh Jain, Director,  E.L. Steele Laboratory of Tumor Biology, MGH Cancer Center/Harvard Medical School
Moderator: Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

Fireside Chat

Dr. Ansbert Gadicke, Founder & Managing Director, MPM Capital; Dr. Stelios Papadopoulos, Chairman, Biogen; Dr. Tsutomu Une, Senior Corporate Advisor, GCA Corporation
Moderator: Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

Panel Discussion: Technology Platforms

Panelists: Chris Benko, Co-Founder and Chief Executive Officer, Koneksa Health; Colin Hill, Chairman & CEO, GNS Healthcare; Dr. Peter Mueller, President, The Mueller Health Foundation; Dr. Shahram Ebadollahi, Vice President, Innovations & CSO, IBM Watson Health Group; Dr. Vijay Chandru, Chairman, Strand Life Sciences
Moderator: Dr. Ajay Dhankhar, Senior Partner, McKinsey and Company

Presentation- BioPharma: An Extraordinary Disruption

Dr. Ajay Dhankhar, Senior Partner, McKinsey and Company; Sastry Chilukuri, Partner, McKinsey and Company

Panel Discussion: Drug Discovery and Development

Panelists: Dr Andrew Plump, Chief Medical and Scientific Officer, Takeda Pharmaceuticals; Dr. Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical- J&J; Dr. Michael Ehlers, Executive Vice President and Head of R&D, Biogen
Moderator: Dr. Martin Mackay, Co-Founder and CEO, Rallybio

Fireside Chat

Dr. George Daley, Dean, Harvard Medical School; Dr. Susan Hockfield, President Emerita & Professor of Neuroscience, Massachusetts Institute of Technology (MIT)
Moderator: Dr Andrew Plump, Chief Medical and Scientific Officer, Takeda Pharmaceuticals

Strategy Sessions Co-Chairs:

External R&D Strategy Session- New Frontiers in External Innovation

Benjamin (Ben) Thorner, Head of Business Development & Licensing, Merck Research Labs
Dr. Ajay Nirula, Vice President- Immunology, Lilly Research Laboratories
Philippe Lopes-Fernandes, Senior Vice President, Merck KGaA, Darmstadt, Germany
Dr. Chandra Ramanathan, Vice President & Head of East Coast Innovation Center, Bayer

Technology Platforms Strategy Session

Dr. Vijay Chandru, Chairman, Strand Lifesciences
Iya Khalil, Co-Founder and Executive Vice President, GNS Healthcare
Dr. Femida Gwadry-Sridhar, Founder and Chief Executive Officer, Pulse Infoframe

11th annual BioPharma & Healthcare Summit Marriott Cambridge, Massachusetts, USA May 18, 2017

Master of Ceremonies- Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals
Welcome address: Karun Rishi, President, USA-India Chamber of Commerce

India Regulatory and Clinical Research Update
Dr. R K Vats , IAS, Additional Secretary, Ministry of Health and Family Welfare, Govt. of India

Panel Discussion: Oncology

Panelists: Dr. Edward Benz, President & CEO Emeritus, Dana Farber Cancer Institute; Dr. Vijay Chandru, Chairman, Strand Life Sciences; Dr. Timothy Clackson, President R&D and CSO, Ariad; Dr. Jeffrey Engelman, Global Head of Oncology Research, NIBR (Novartis); Dr. Rakesh Jain, E.L. Steele Laboratory of Tumor Biology,  MGH Cancer Center

Moderator: Dr. Vijay Kuchroo, Director- Evergrande Center, Brigham & Women's Hospital/ Harvard Medical School

Fireside Chat with Dr. Richard Moscicki, Deputy Director (Science Operations), Center for Drug Evaluation and Research, USFDA; Dr. GN Singh, Drug Controller General of India, CDSO, Ministry of Health and Dr. Chris Austin, Director, National Center for Advancing Translational Sciences, National Institutes of Health
Moderator: Dr. William Chin, Executive Vice President and Chief Medical Officer, PhRMA

Panel Discussion: Vaccines

Panelists: Dr. Stephen Caddick, Director of Innovation, Wellcome Trust; Dr. Johan Van Hoof, Global Therapeutic Head- Infectious Diseases & Vaccines, Janssen Pharmaceutical Companies of Johnson &Johnson; Dr. Gagandeep Kang, Executive Director, Translational Health Science & Technology Institute ; Michael Nally, President, Merck Vaccines, Merck & Co; Dr. Niranjan Sardesai, Chief Operating Officer, Inovio Pharmaceuticals
Moderator: Dr. William Chin, Executive Vice President and Chief Medical Officer, PhRMA

Fireside Chat with Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co. and Dr. R. K. Vats, IAS, Additional Secretary, Ministry of Health and Family Welfare, Government of India

Moderator: Dr. Amrit Ray, Chief Medical Officer, Janssen Pharmaceutical Companies of Johnson & Johnson

Panel Discussion: Clinical Trials & Regulatory

Panelists: Dr. Richard Moscicki, Deputy Director (Science Operations), CDER, USFDA ; Dr. Petra Kaufmann, Director, Office of Rare Diseases Research & Director, Division of Clinical Innovation- NCATS, National Institutes of Health; Dr. GN Singh, Drug Controller General of India, CDSO, Ministry of Health; K.V. Subramaniam, President, Reliance Life Sciences ; Dr. Tsutomu Une, Corporate Advisor, GCA Corporation
Moderator: Dr. Michael Rosenblatt, Chief Medical Officer, Flagship Pioneering

Panel Discussion: Rare and Neglected Diseases                                                                            

Panelists: Dr. Chris Austin, Director, National Center for Advancing Translational Sciences, National Institute of Health; Dr. Jim Burns, President and CEO, Casebia Therapeutics; Dr David Meeker, Head, Sanofi Genzyme; Dr. Wim Parys, Head of R&D- Global Public Health, Janssen Pharmaceutical- Johnson &Johnson; Dr. Alfred Sandrock, Executive Vice President & Chief Medical Officer, Biogen
Moderator: Dr. Steve Uden, Head of Research, Alexion Pharmaceuticals

Panel Discussion: Drug Discovery and Development

Panelists: Dr. James Bradner, President, Novartis Institutes for BioMedical Research; Dr. William Hait, Global Head- Research & Development, Janssen Pharmaceutical- Johnson &Johnson; Dr. David Nicholson, Chief R&D Officer, Allergan; Dr Andrew Plump, Chief Medical & Scientific Officer and Director, Takeda
Moderator: Dr. Martin Mackay, Exe. Vice President and Global Head of R&D, Alexion Pharmaceuticals

Strategy Sessions Co-Chairs:

Rare & Neglected Diseases strategy session
Petra Kaufmann, MD, Director- Office of Rare Diseases Research, Director- Division of Clinical Innovation, National Institutes of Health (NIH)
Philippe Lopes-Fernandes, Senior Vice-President, Head of Global Business Development & Alliance Management, Merck KGaA
Sanjeev Sinha, MD, Professor, Department of Medicine, All India Institute of Medical Sciences (AIIMS)
Vijay Chandru, PhD, Chairman & CEO, Strand Life Sciences

External R&D strategy session
Manni Kantipudi, Chief Executive Officer, GVK BIO
Robert Urban, PhD, Global Head, Johnson & Johnson Innovation
Sridaran Natesan, PhD, Vice President- Strategic Initiatives & Scientific Relations, Sanofi

10th annual BioPharma & Healthcare Summit Marriott Cambridge, Massachusetts, USA June 2, 2016

Master of Ceremonies- Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals

Welcome address: Karun Rishi, President, USA India Chamber of Commerce

India Regulatory and Clinical Research Update
K.L. Sharma, IAS, Joint Secretary, Ministry of Health and Family Welfare, Government of India

Panel Discussion: Neurodegenerative diseases- Matters of the mind

Panelists: Dr. John Dunlop, Vice President & Head, Neuroscience, AstraZeneca; Dr. Douglas Feltner; Philippe Lopes-Fernandes, Senior Vice-President, Merck KGaA; Dr. Alfred Sandrock, Executive Vice President and Chief Medical Officer, Biogen; Dr. Rudolph Tanzi, Director, Genetics and Aging Research Unit, Mass General Hospital
Moderator: Dr. Ole Isacson, Professor of Neurology, Harvard Medical School

Fireside Chat with Dr David Meeker, Head, Sanofi Genzyme and Dilip Shanghvi, Managing Director, Sun Pharmaceutical Industries Limited
Moderator:
Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

Panel Discussion: Drug Discovery and Collaborative Research: The path forward

Panelists: Dr. Ariz Ahammed IAS, Joint Secretary, Department of Pharmaceuticals, Govt. of India; Dr. Barry Bloom, Distinguished Service Professor, Harvard School of Public Health; Dr. Peter Mueller, President of R&D and Chief Scientific Officer, Pronutria BioSciences; Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals; Anil Raghavan, Chief Executive Officer, Sun Pharma Advanced Research Company
Moderator: Dr. Steve Uden, Head of Research, Alexion Pharmaceuticals

Fireside Chat with Dr Griffin Rodgers, Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health
Moderator:
Dr. William Chin, Executive Vice President, PhRMA

Panel Discussion: Oncology- Immuno-oncology, data analytics and value platforms - the new world order

Panelists: Dr. Bruce Chabner, Director of Clinical Research, MGH Cancer Center; Dr. Arun Chandavarkar, CEO & Joint Managing Director, Biocon; Dr. Gordon Freeman, Professor of Medicine, Dana-Farber Cancer Institute/HMC; Dr. Sandeep Gupta, President & CEO, Asana BioSciences; Dr. Rakesh Jain, E.L. Steele Laboratory of Tumor Biology,  MGH Cancer Center; Dr. Daniel Omstead, President & CEO,Tekla Capital Management
Moderator: 
Colin Hill, Chairman & CEO, GNS Healthcare

Panel Discussion: Cardiovascular and Metabolic Diseases- Matters of the heart and the body

Panelists: Neil McDonnell, PharmD, Chief Executive Officer, Metacrine; Dr. Anthony Muslin, Vice President, Head of the Cardiovascular & Fibrosis Unit, Sanofi; Dr. Robert Plenge, VP and  Head of Translational Medicine, Merck Research Labs; Dr. Arthur Tzianabos, President & CEO, Homology Medicines; Dr. Murali Vemula, Founder & President, Nivarta
Moderator: Dr. Michael Rosenblatt, Executive Vice President & Chief Medical Officer, Merck & Co.

Panel Discussion: Regulatory Policies to foster R&D Innovation

Panelists: Dr. Ariz Ahammed IAS, Joint Secretary, Department of Pharmaceuticals, Govt. of India; Dr. Christopher Corsico, Chief Medical Officer, Boehringer Ingelheim GmbH; Rajiv Kaul, Portfolio Manager, Fidelity Investments; K.L. Sharma, IAS, Joint Secretary, Ministry of Health & Family Welfare, Govt. of  India; Dr. Tsutomu Une, Corporate Advisor, Daiichi Sankyo Co., Ltd.
Moderator: 
Dr. William Chin, Executive Vice President, PhRMA

Comments from past Participants (Those who have been participating for 9 years or longer)

Sanjeev Gupta, MD, Professor of Medicine,  Albert Einstein College of Medicine; Amar Sawhney, Chairman & CEO, Ocular Therapeutix; Dinesh Patel, MD, Chief of Arthroscopic Surgery, Mass General Hospital; Vijay Chandru, PhD, Chairman, Strand Life Sciences; Ajay Dhankhar, PhD, Senior Partner, McKinsey & Company; Sunil Shah, Chief Executive Officer, O2h; Manni Kantipudi, Chief Executive Officer, GVK Biosciences; Sridaran Natesan, PhD, Vice President -Strategic Initiatives & Scientific Relations, Sanofi; Christopher Wright, MD, PhD, Chief Medical Officer, Axcella Health; Srini Srinivasan, Managing Director, Hospira Healthcare India; Glenn Kazo, President, Prolong Pharmaceuticals; William Chin, MD, Executive Vice President, PhRMA; Raju Kucherlapati, PhD, Professor of Genetics, Harvard Medical School

Strategy Sessions Co-Chairs:

Genetics & Genomics
Dr. Kush Parmar, Managing Partner, 5AM Ventures
Dr. John Reynders, Vice President, Alexion
Dr. Vijay Chandru, Chairman, Strand Lifesciences

External Research Strategies
Dr. Sridaran Natesan, Vice President, Sanofi USA
Dr. Meeta Chatterjee, Head of Business Strategy and Operations, Merck Research Labs
Dr. Sanjeev Sinha, Professor, All India Institute of Medical Sciences

9th annual BioPharma & Healthcare Summit Marriott Cambridge, Massachusetts, USA June 11, 2015

Master of Ceremonies- Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School
Welcome address: Karun Rishi, President, USA India Chamber of Commerce

Fireside Chat with Christopher Viehbacher, Puretech Ventures and Dr. Tachi Yamada, Chief Medical & Scientific Officer, Takeda
Moderator:  Dr. William Chin, Executive Vice President, PhRMA

Chief Medical Officer’s Panel: Can the CMO make or break the India value proposition?

Panelists: Dr. Timothy Garnett, Chief Medical Officer, Lilly Research Laboratories; Dr. Jagdish Prasad, Director General Health Services, Ministry of Health, India; Dr. Amrit Ray, Chief Medical Officer, Janssen; Dr. Maria Rivas, Vice President, Global Medical Affairs, AbbVie; Dr. Michael Rosenblatt, Executive Vice President & Chief Medical Officer, Merck & Co.
Moderator: Dr. William Chin, Executive Vice President, PhRMA

Panel Discussion: Oncology- High potential but high cost – Can emerging markets like India help drive affordable innovation at scale?

Panelists: Dr. Edward Benz, President & CEO, Dana Farber Cancer Institute; Dr. Bruce Chabner, Director of Clinical Research, MGH Cancer Center; Dr. Vijay Chandru, Chairman & CEO, Strand Life Sciences; Dr. Sandeep Gupta, President & CEO, Asana BioSciences; Dr. Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon
Moderator: Dr. Maya Said, Vice President-Strategy, External Innovation & Science Policy, Sanofi
 
Panel Discussion: Cardiovascular and Metabolic Diseases - How can we turn the tide on the world’s largest culprit for disease burden and mortality?

Panelists: Dr. Judith Fradkin, Director, Division of DE&MD, NIDDK, National Institutes of Health; Dr. Philip Larsen, Global Head of Diabetes R&D, Sanofi; Dr. Jagdish Prasad, Director General Health Services, Ministry of Health, India; Dr. Peter Stein, VP, Late Stage Development, Diabetes & Endocrinology, Merck Research Labs; Dr. Carani Sanjeevi, Professor, Department of Medicine, Karolinska Institute
Moderator: Dr. Roger Newton, Founder, Executive Chairman & CSO, Esperion Therapeutics

Panel Discussion: Drug Discovery and Collaborative Research- Increasing the odds of success

Panelists: Dr. Peter Mueller, President of R&D and Chief Scientific Officer, Pronutria BioSciences; Dr. John Orloff, Global Head of R&D, Baxalta; Dr. Andrew Plump, Chief Medical & Scientific Officer Delegate, Takeda; Dr. Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon; Dr. Tsutomu Une, Corporate Advisor, Daiichi Sankyo Co., Ltd.
Moderator: Dr. Martin Mackay, Executive Vice President and Global Head of R&D, Alexion Pharmaceuticals

Panel Discussion: Neurodegenerative Diseases - Will we be able to contain the “epidemic” ahead of us?

Panelists: Dr. Jang-Ho Cha, Global Head, Translational Medicine, Neuroscience, Novartis Institutes for Biomedical Research; Dr. Peter Lansbury, Chief Scientific Officer, Lysosomal Therapeutics; Dr. Darryle Schoepp, VP & Neuroscience TA Head, Early Dev, Merck & Co; Dr. Todd Sherer, Chief Executive Officer, The Michael J. Fox Foundation (MJFF); K.V. Subramaniam, President, Reliance Life Sciences 
Moderator: Dr. Ole Isacson, Professor of Neurology, Harvard Medical School

Strategy Sessions Co-Chairs

Big Data
Collin Hill, Chairman & CEO, GNS Healthcare
Dr. Azmi Nabulsi, Head of R&D Strategic and Professional Affairs, Takeda
External R&D Strategies
Philippe Lopes-Fernandes, Senior Vice-President, Merck Serono / EMD Serono
Dr. Sandeep Gupta, President & CEO, Asana BioSciences

Release of Position Paper by Advisory Board members
Presentation of USA-India Chamber of Commerce commissioned Position Paper by 
Patrick Figgis,  Global Leader, Health and Sujay Shetty, Partner, India Pharma Life Sciences, Pricewaterhouse Coopers LLP

Delhi Strategy Session The Leela Palace, New Delhi February 18, 2015

We regret over 100 senior colleagues could not be accommodated in this meeting due to the nature and format of this Strategy Session. Detailed report with recommendations has been sent to the participants, members and key policy makers.

Co-Chairs:

Prof. Ranjit Roy Chaudhury, Chairman- Task Force for Research, Apollo Hospitals
Krishna Ella, Chairman, Bharat Biotech
Dr. G.N. Singh, Drug Controller General of India, Central Drug Control Organization
Dr. Une Tsutomu, Corporate Advisor, Daiichi Sankyo
Dr. M.K. Bhan, Former Secretary to Government of India, Department of Biotechnology
V.K. Subburaj, Secretary to the Government of India, Department of Pharmaceuticals
Davinder Brar, Chairman, GVK Biosciences
Dr, Naresh Trehan, Chairman, Medanta
Dr. Nirmal K. Ganguly, Professor, National Institute of Immunology
Dr. William Chin, Executive Vice President, PhRMA
K.V. Subramaniam, Chief Executive Officer, Reliance Life Sciences
Karun Rishi, President, USA India Chamber of Commerce
Patrick Figgis, Partner & Global Leader –Health, PricewaterhouseCoopers

Delhi Strategy Session reflected on the action agenda emerging from the global summit held in June 2014 in Boston, explored the implications for the decision makers in India and discussed ideas for the June 11, 2015 Boston Summit. PricewaterhouseCoopers facilitated the session. We will take the lead to develop deeper perspectives on these issues through detailed stakeholder discussions, interviews and analyses for discussion at the Boston summit in June 2015

Discussions were held on:
1. India’s potential R&D strengths and steps required to play a leading role in BioPharma & Healthcare innovation
2. Regulatory environment to spur innovation
3. Clinical Trials
4. Suggestions for the 2015 Boston BioPharma Summit

8th annual BioPharma & Healthcare Summit Marriott Cambridge, Massachusetts, USA June 27, 2014

Master of Ceremonies: Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School
Welcome Address: Karun Rishi, President, USA-India Chamber of Commerce
Address by: Professor K. VijayRaghavan, Secretary, Department of Biotechnology, Ministry of Science & Technology, Government of India
Address by: Dr. Robert Langer, David H. Koch Institute Professor, MIT

Panel Discussion: Biologics and Biosimilars- How will the future landscape shape out and what are the key challenges to overcome?

Panelists: John Cox, Executive Vice President- Pharma Operations, Biogen Idec; Dr. Richard Gregory, Head of R&D, Sanofi-Genzyme R&D Center; Dr. Mark Schenerman, Vice President- Analytical Biotechnology & Strategy, MedImmune; Rick Srigley, President & CEO, Aragen Bioscience; K.V. Subramaniam, President & CEO, Reliance Life Sciences 

Moderator: Thomas Saylor, Chief Executive Officer, Arecor Limited

Panel Discussion:  Industry-Academia Partnerships- Is there a recipe for successful partnerships?

Panelists: Dr. Karen Antman, Dean and Provost, Boston University School of Medicine ; Dr. Sumantra Chattarji, NCBS, Director- Center for Brain Development & Repair, India; Dr. Laurie Glimcher, Dean, Weill Cornell Medical College; Dr. Michael Rosenblatt, Executive Vice President & Chief Medical Officer, Merck & Co.; Dr. Lansing Taylor, Director, University of Pittsburgh Drug Discovery Institute

Moderator: Dr. William Chin, Executive Vice President- Scientific and Regulatory Affairs, PhRMA

Panel Discussion: Reimagining India- Unlocking the potential of Asia’s next superpower

Panelists: Dr. Yasheng Huang, Associate Dean and Professor, Sloan School of Management- MIT; Ambassador Dnyaneshwar Mulay, Consul General of India, New York; Prof. K. VijayRaghavan, Secretary, Department of Biotechnology, Govt. of India; Dr. Srinath Reddy, President, Public Health Foundation of India

Moderator: Adil Zainulbhai, Director Emeritus - India Office, McKinsey & Company

Panel Discussion: Drug Discovery and Collaborative Research- How can emerging markets play a greater role in BioPharma innovation?

Panelists: Dr. Subir Basak, President- Global Drug Discovery Services, Jubilant Life Sciences; Dr. Bahija Jallal, Executive Vice President, MedImmune; Manni Kantipudi, Chief Executive Officer, GVK Biosciences; Dr. Andrew Plump, Deputy President of Global R&D, Sanofi; Dr. Tsutomu Une, Corporate Advisor, Daiichi Sankyo Co., Ltd.

Moderator: Dr. Martin Mackay, Executive Vice President and Global Head of R&D, Alexion Pharmaceuticals

Panel Discussion: Cardiovascular and Metabolic Diseases- Science and research trends- Lessening the disease burden through BioPharma innovation

Panelists: Dr. Caroline Apovian, Professor of Medicine, Section of Endocrinology, Boston University Medical Center; Dr. Daniel Bloomfield, Vice President Clinical Research and  Cardiovascular Therapeutic Area Head, Merck Research Labs; John Brooks, President & CEO, Joslin Diabetes Center; Dr. Philip Larsen, Global Head of Diabetes R&D, Sanofi; Dr. Ming Wang, Vice President and Disease Area Leader of Diabetes, Janssen Pharmaceuticals
Moderator: Sri Mosur, President, Stabilis and Founder, Tanroe

Release of Position Paper by Advisory Board members
Presentation of USA-India Chamber of Commerce commissioned Position Paper by Dr. Ajay Dhankhar, Director and Dr. Jeffrey Smith, Partner - McKinsey & Company

Cocktails and Networking Reception

Delhi Strategy Session The Oberoi, New Delhi February 6, 2014

We regret over 90 senior colleagues could not be accommodated in this meeting due to the nature and format of this Strategy Session. Detailed report with recommendations has been sent to the participants, members and key policy makers.

Co-Chairs:
Prof. K. VijayRaghavan, Secretary, Department of Biotechnology
Dr. Tsutomu Une, Member of the Board, Daiichi Sankyo
Dr. Naresh Trehan, Chairman, Medanta- The Medicity
Dr. G.N. Singh, Drug Controller General of India
Dr. Willard Dere, Senior Vice President & Global CMO, Amgen
D.S. Brar, Chairman, GVK Biosciences
Prof. N.K. Ganguly, former Director General, Indian Council for Medical Research
K.V. Subramaniam, Chief Executive Officer, Reliance Life Sciences
Dr. Narinder Mehra, Dean for Research, All India Institute of Medical Sciences
Dr. Ajay Dhankhar, Director, McKinsey & Company
Karun Rishi, President, USA-India Chamber of Commerce

Delhi Strategy Session reflected on the action agenda emerging from the global summit held in June 2013 in Boston, explored the implications for the decision makers in India and discussed ideas for the June 27, 2014 Boston Summit. McKinsey & Company facilitated the session. We will take the lead to develop deeper perspectives on these issues through detailed stakeholder discussions, interviews and analyses for discussion at the Boston summit in June 2014.

Discussions were held on:

1. R&D challenges and models: Clinical trials; public-private partnerships
2. Regulatory environment to spur innovation: How can India play a more leading role?
3. Biologics & Biosimilars: Can Indian talent and extensive unmet patient needs be used to help drive further growth and development?
4. Diabetes and Cardiovascular disease: What are disease specific implications on the above topics?

7th annual BioPharma & Healthcare Summit Marriott Cambridge, Massachusetts, USA June 21, 2013

Master of Ceremonies - Dr. Martin Mackay, Exe. Vice President and Global Head of R&D, Alexion Pharmaceuticals 
Welcome Address: Karun Rishi, President, USA-India Chamber of Commerce
Address by: Dr. Elias Zerhouni, President- Global Research & Development, Sanofi
Address by: Ravinder Jain, IAS, Additional Secretary, Ministry of Health, Govt. of India

Panel Discussion: Oncology: Science and Research Trends – High potential but high cost – Can emerging markets help drive affordable innovation at scale?

Panelists: Dr. Ramesh Deka, Director, All India Institute of Medical Sciences; Dr. Willard Dere, Senior Vice President & International Chief Medical Officer, Amgen; Dr. Ansbert Gadicke, Managing Partner, MPM Capital; Dr. Richard Gaynor, Vice President- Oncology Development, Eli Lilly and Company; Dr. Rakesh Jain, E.L. Steele Laboratory of Tumor Biology, MGH Cancer Center
Moderator: Dr. Raju Kucherlapati, Paul C. Cabot Professor, Dept. of Genetics, Harvard Medical School

Panel Discussion:  Infectious Diseases: Science and Research trends– Can global partnerships address a potentially significant public health challenge?

Panelists: Dr. Jeffrey Chodakewitz, SVP & Franchise Head - Infectious Diseases, Merck & Co.; Dr. Brian Dannemann, Senior Director, J&J Pharmaceutical R&D; Dr. Lynn Marks, SVP- Projects, Clinical Platforms & Sciences, GlaxoSmithKline; Dr. Mark Namchuk, Senior Vice President- Research, Vertex Pharmaceuticals; Dr. G.N. Singh, Drug Controller General of India, Central Drug Control Organization
Moderator: Dr. Manos Perros, Head of Infection iMed & Site Head, Boston R&D, AstraZeneca

Panel Discussion: Industry-Academic Partnerships/Translational Research: Is there a recipe for successful partnerships?

Panelists: Dr. Karen Antman, Dean and Provost, Boston University School of Medicine; Dr. Sanjeevi Carani, Associate Professor, Karolinska Institutet; Dr. JC Gutiérrez-Ramos, Group Senior Vice President, Biotherapeutics R&D, Pfizer; Dr. Ashok Kumar, Vice Chancellor, AKS University; Dr. Sridaran Natesan, Vice President, External Innovation (R&D), Sanofi
Moderator: Dr. William Chin, Executive Dean for Research, Harvard Medical School

Panel Discussion: Funding innovation – Building collaborative platforms and supportive policies to foster innovation

Panelists: Shambhu Kallolikar, IAS, Joint Secretary, Department of Pharmaceuticals, Govt. of India; Peter Michelsen, Managing Director, Goldman Sachs; Dr. Helmut Schühsler, Managing Partner, TVM Capital; Dr. G.N. Singh, Drug Controller General of India, Central Drug Control Organization; K.V. Subramaniam, President & CEO, Reliance Life Sciences
Moderator: Navjot Singh, Director, McKinsey and CompanyPanel Discussion: Drug discovery and Collaborative Research- Are existing R&D models doing enough to address the global productivity challenge?

Panelists: Dr. Subir Basak, President- Global Drug Discovery Services, Jubilant Life Sciences; Dr. Martin Fitchet, Chief Operating Officer, Janssen Research & Development; Dr. Bahija Jallal, Executive Vice President, MedImmune; Dr. Peter Mueller, Exe. Vice President - Global R&D & CSO, Vertex Pharmaceuticals; Dr. Maya Said, Vice President Strategy, Ext. Innovation & Science Policy (R&D), Sanofi
Moderator: Dr. Martin Mackay, Exe. Vice President and Global Head of R&D, Alexion Pharmaceuticals

Strategy Sessions Co-Chairs
Industry Academic Research Partnerships 
Dr. Barbara Bierer, Senior Vice President- Research, Brigham and Women’s Hospital
Dr. Sridaran Natesan, Vice President, External Innovation (R&D), Sanofi
Dr. José-Carlos Gutiérrez-Ramos, Senior Vice President, Head of BioTherapeutics R&D, Pfizer

External R&D Strategies
Dr. Subir Basak, President- Drug Discovery Services, Jubilant Life Sciences
Dr. RuiPing Dong, Senior Vice President, Head of Emerging Markets R&D, Merck & Co.
Dr. Jeffrey S. Nye, Vice President, Neuroscience Innovation and Scientific Partnership Strategy
Janssen Research and Development, Johnson and Johnson Innovation

Release of Position Paper by Advisory Board members
Presentation of USA-India Chamber of Commerce commissioned Position Paper by Dr. Ajay Dhankhar, Director and Vikas Bhadoria, Principal - McKinsey & Company

Cocktails and Networking Reception

Delhi Strategy Session The Leela Palace, New Delhi February 1, 2013

We regret over 100 senior colleagues could not be accommodated in this meeting due to the nature and format of this Strategy Session. Detailed report with recommendations has been sent to the participants, members and key policy makers.

Co-Chairs:
Dr. T. Ramasami, Secretary, Department of Science & Technology 
Dr. M.K. Bhan, Former Secretary, Department of Biotechnology
Tsutomu Une, PhD, Member of the Board, Daiichi Sankyo
Richard Mills, JD, Executive Dean, Harvard Medical School
Dr. Naresh Trehan, Chairman, Medanta- The Medicity
Dr. Jagdish Prasad, Director General Health Services, Ministry of Health & Family Welfare
Edward Trimble, MD, MPH Director Global Health, National Cancer Institute
Prof. N.K. Ganguly, Chairman, JIPMER
Karun  Rishi, President, USA-India Chamber of Commerce

Delhi Strategy Session reflected on the action agenda emerging from the global summit held in May  2012 in Boston, explored the implications for the decision makers in India and discussed ideas for the June 21, 2013 Boston Summit. McKinsey & Company facilitated the session. We will take the lead to develop deeper perspectives on these issues through detailed stakeholder discussions, interviews and analyses for discussion at the Boston summit in June.

Discussion were held on Key Enablers:
A.        Industry Academic Partnerships
B.        Talent and Capability Building
C.        External Research Strategies
D.        Building A Regulatory Environment to Foster Innovation

6th annual BioPharma & Healthcare Summit Hyatt Cambridge, Massachusetts, USA May 11, 2012

Master of Ceremonies: Dr. William Chin, Executive Dean for Research, Harvard Medical School
Welcome Address: Karun Rishi, President, USA-India Chamber of Commerce
Address By: Dr. Elias Zerhouni, President- Global Research & Development, Sanofi

Strategy Sessions Co-Chairs
Noble Laureate Dr. Phillip Sharp, Institute Professor, Koch Institute for Integrative Cancer Research, MIT
Dr. Sridaran Natesan, Vice President, External Innovation (R&D), Sanofi
Dr. Sanjeev Sinha, Professor- Department of Medicine, All India Institute of Medical Sciences
Dr. RuiPing Dong, Senior Vice President, Head of Emerging Markets R&D, Merck & Co.
Dr. Sandeep Gupta, Sr. Vice President- Early Discovery, Endo Pharmaceuticals
Dr. Rick Connell, VP- External Research Solutions, Pfizer
Sri Mosur, CEO, Global Drug Discovery & Development, Jubilant Life Sciences 

Panel Discussion: Industry-Academia Partnerships- Can they drive the next wave of innovation? 

Panelists: Dr. Karen Antman, Dean and Provost, Boston University School of Medicine; Dr. Barbara Bierer, Senior Vice President Research, Brigham and Women's Hospital; Dr. Balakrish Nair, Executive Director, Translational Health Science Technology Institute; Dr. Sridaran Natesan, Vice President, External Innovation (R&D), Sanofi; Dr. Phillip Sharp, Institute Professor, Koch Institute for Integrative Cancer Research
Moderator: Dr. William Chin, Executive Dean for Research, Harvard Medical School. 

Panel Discussion: Clinical Research- A practical roadmap to achieve more from India 

Panelists: Dr. Savita Dhillon, Medical Director, Medanta Duke Research Institute; Dr. Nirmal K. Ganguly, Chairman JIPMER & former Director General ICMR; Dr. Roger Glass, Director, Fogarty International Center, National Institutes of Health; Dr. John Orloff, Senior Vice President, Global Development & CMO, Novartis; Dr. John Sundy, Director- Duke Global Proof of Concept Research Network
Moderator: Dr. Kimberly Wagner, Senior Partner & Managing Director, The Boston Consulting Group

Panel Discussion: Drug R&D and Collaborations- Leveraging India to enhance productivity

Panelists: Dr. Ivan Gergel, Executive Vice President R&D, Endo Pharmaceuticals; Dr. John Leonard, Senior Vice President- Pharmaceuticals R&D, Abbott; Sri Mosur, CEO, Global Drug Discovery & Development, Jubilant Life Sciences; Dr. Rajiv I. Modi, Managing Director, Cadila Pharmaceuticals; Dr. Raja Sekhar Vundru, IAS,  Joint Secretary, Department of Pharmaceuticals, Govt. of India
Moderator: Dr. Maya Said, Vice President Strategy, External Innovation & Science Policy (R&D), Sanofi 

Panel Discussion: Funding innovation and investment opportunities in Emerging Markets

Panelists: Dr. RuiPing Dong, Senior Vice President, Head of Emerging Markets R&D, Merck & Co; Dr. Robert King, Senior Partner, Global Healthcare Group, Goldman Sachs; Utkarsh Palnitkar, Executive Director, Centrum Capital Limited; K.V. Subramaniam, President & CEO, Reliance Life Sciences; Dr. Renu Swarup, Managing Director, Biotechnology Industry Research Assistance Council, Government of India
Moderator: Bart Janssens, Partner & Managing Director, The Boston Consulting Group

Panel Discussion: Oncology- Science and Research Trends

Panelists: Dr. Nirmal K. Ganguly, Chairman JIPMER & former Director General ICMR; Dr. Rakesh Jain, E.L. Steele Laboratory of Tumor Biology,  MGH Cancer Center; Dr. Amba Nandakumar, Deputy Director General and  Officer-in-Charge,
National Cancer Registry Programme- Indian Council for Medical Research; Dr. Elad Sharon, Senior Investigator, Investigational Drug Branch, National Cancer Institute; Dr. Chris Takimoto, Vice President, Translational Medicine Early Development, J&J
Moderator: Dr. Raju Kucherlapati, Paul C. Cabot Professor, Department of Genetics, Harvard Medical School

Presentation of USA-India Chamber of Commerce commissioned Position Paper by Bart Janssens, Partner and Rahul Guha, Principal- The Boston Consulting Group

Cocktails and Networking Reception

Delhi Summit Strategy Session The Oberoi, New Delhi November 11, 2011

Co-Chairs:

• Dr. MK Bhan, Secretary to the Government of India, Department of Biotechnology
• Dr. Nirmal K. Ganguly, Chairman JIPMER, past Director General- ICMR
• Dr. T. Ramasami, Secretary to the Government of India, Department of Science & Technology
• Dr. V.G. Somani, Drug Controller General of India
• Dr. Sandeep Gupta, Senior Vice President, Endo Pharmaceuticals
• Karun Rishi, President, USA-India Chamber of Commerce
• DS Brar, Chairman, GVK Biosciences
• KV Subramaniam, CEO, Reliance Life Sciences

Program Summary:
Action agenda emerging from USAIC’s annual global summit
Explore the implications for decision makers in India 
Discuss the agenda for the 2012 summit

5th annual BioPharma & Healthcare Summit Hyatt Regency, Cambridge Massachusetts, USA June 23, 2011

Program Summary 

Master of Ceremonies - Dr. Bill Chin, Executive Dean for Research, Harvard Medical School
Opening remarks: Karun Rishi, President-USA-India Chamber of Commerce

Panel Discussion: Drug Discovery and Collaborative Research: Increasing the odds of success

Panelists: Dr. Martin Fitchet, Chief Operating Officer, Johnson & Johnson Pharma R&D; Dr. Ivan Gergel, Executive Vice President R&D, Endo Pharmaceuticals; Dr. John Leonard, Senior Vice President- Pharmaceuticals R&D, Abbott; Sri Mosur, CEO, Global Drug Discovery & Development, Jubilant Life Sciences; Dr. Peter Mueller, Executive Vice President- Global R&D, Vertex Pharmaceuticals
Moderator: Dr. Bill Chin, Executive Dean for Research, Harvard Medical School

Panel Discussion: "Show me the Money": Funding innovation, investment opportunities and cross border M&A trends in the BioPharma & Healthcare

Panelists: Hari Bhartia, Founder & Co-Chairman, Jubilant Bhartia Groups; Dr. Ansbert Gadicke, Founder & Managing Director, MPM Capital; Robert King, Senior Partner, Global Healthcare Group, Goldman Sachs; Joel Marcus, Chairman & CEO, Alexandria Real Estate Equities; K.V. Subramaniam, President, Reliance Life Sciences
Moderator: Jeff Elton, Founder & CEO, KEW Group

Panel Discussion: Industry-Academia Partnerships: Can they be the engine of a new wave of innovation?

Panelists: Dr. Harris Berman, Dean ad interim, Tufts University School of Medicine; Dr. M.K. Bhan, Secretary, Department of Biotechnology, Govt. of India; Dr. Vijay Chandru, Chairman & CEO, Strand Life Sciences; Julius Knowles, Head, Platforms, Strategic Alliances, NIBR (Novartis); Dr. Lansing Taylor, Director, Drug Discovery Institute, University of Pittsburg
Moderator: Dr. Barry Bloom, Distinguished Service Professor, Harvard School of Public Health

Panel Discussion: Diabetes - Science, Research trends and Market Opportunities

Panelists: Dr. Martin Fitchet, Chief Operating Officer, Johnson & Johnson Pharma R&D; Dr. William Mezzanotte, Vice President- Global Products Leadership, AstraZeneca; Dr. Steven Shoelson, Professor of Medicine, Joslin/Harvard Medical School; Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon; Dr. Suri Venkatachalam, Founder & CEO, Connexios Life Sciences
Moderator: Dr. Paul Strumph, Vice President-Therapeutic Strategy Lead, Quintiles

Panel Discussion: Moving the needle on Drug Development, Clinical Research & other Healthcare opportunities

Panelists: Dr. Nora Dyer, Head of Search & Evaluation, Novartis Pharmaceuticals; Dr. Nirmal Ganguly, Chairman JIPMER, & ex-Director General ICMR; Krishna Kanumuri, Chief Executive Officer, Sai Advantium; Sanjay Mittal, Director- Research & Clinical Cardiology, Medanta -The Medicity; Debasish Roychowdhury, Head of Global Oncology, Sanofi
Moderator: Dr. Gunther Winkler, Senior Vice President, Biogen Idec

Presentation of USA-India Chamber of Commerce commissioned annual Position Paper by Bart Janssens, Partner, The Boston Consulting Group

Strategy Sessions Co-Chairs
Richard D. Connell, PhD, Vice President and Head of Asia Research, Pfizer
Sandeep Gupta, PhD, Senior Vice President of Drug Discovery & Early Development, Endo Pharmaceuticals
Sri Mosur, President & CEO, Global Drug Discovery & Development, Jubilant Life Sciences
Isaac T. Kohlberg, Senior Associate Provost & Chief Technology Development Officer, Harvard
Sridaran Natesan, PhD, Scientific Site Head - R&D & Head External Innovation & Partnering- NE, Sanofi

Cocktails and Networking Reception 

4th annual BioPharma & Healthcare Summit Hyatt Regency Cambridge, Massachusetts, USA May 6, 2010

Master of Ceremonies - Dr. Martin Mackay, President Global R&D, Pfizer
Opening Remarks: Karun Rishi, President, USA India Chamber of Commerce

Panel Discussion: Industry-Academia Partnerships

Panelists: Dr. Allen M Spiegel, Dean, Albert Einstein College of Medicine, Yeshiva University; Balu Balasubramanian, PhD, Managing Director, BMS-Biocon R&D Center; Dr. David Golan, Dean of Graduate Education, Harvard Medical School; Dr. Nirmal Ganguly, Chairman JIPMER, Ex-Director General ICMR; Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon
Moderator: Dr. Barry R. Bloom Distinguished Service Professor, Harvard School of Public Health

Panel Discussion - Funding innovation, investment opportunities and cross
border M&A trends in US-India BioPharma & Healthcare

Panelists: Joel Marcus, Chariman and CEO, Alexandria; K.V. Subramaniam, President & CEO, Reliance Life Sciences; Dr. Ansbert Gadicke, Founder & Managing Director, MPM Capital; Utkarsh Palnitkar, Executive Director, Centrum Capital Limited; Brian Atwood, Founding Partner, Versant Ventures
Moderator: Jeff Elton, Founder & CEO, KEW Group

Presentation by: Dr. Marc Cluzel, Executive Vice President & Global Head of R&D, Sanofi aventis - From Preferred Partner to Preferred Network

Presentation by: Dr. Mervyn Turner, Chief Strategy Officer & Senior Vice President Emerging Markets R&D, Merck & Co. - How can India foster innovation in Health Care?

Panel Discussion: Collaborative Research and Drug Discovery

Panelists: Dr. David Lacey, Senior Vice President- Research, Amgen; Dr. Peter Mueller, Executive Vice President, Global R&D & CSO, Vertex Pharmaceuticals; Sri Mosur, Chief Executive Officer, Jubilant Biosys; Dr. Paul Stoffels, Global Head- R&D Pharma, Johnson & Johnson; Davinder Brar, Chairman, GVK Biosciences
Moderator: Dr. Martin Mackay, President PharmaTherapeutics R&D, Pfizer 

Presentation by: Dr. Rod MacKenzie, Senior Vice President & Head of Worldwide Research, PharmaTherapeutics, Pfizer - Pfizer in India

Panel Discussion: Drug Development, Clinical Research & Healthcare opportunities

Panelists: Dr. Michael Rosenblatt, Executive Vice President & Chief Medical Officer, Merck & Co.; Dr. Sanjay Mittal, Director-Clinical Cardiology & Research, Medanta, The Medicity; Dr. Nirmal Ganguly, Chairman JIPMER, Ex-Director General ICMR; Dr. Paul Stoffels, Global Head- R&D Pharma, Johnson & Johnson; Dr. Robert Taber Vice Chancellor- Corporate & Venture Devp, Duke University Medical
Moderator: Alka Goel, Associate Principal, McKinsey & Company

Presentation of USA India Chamber of Commerce commissioned McKinsey & Company Position Paper
Ajay Dhankar and Vikas Bhadoria

Closing Remarks - Dr. Gunther Winkler, Sr. Vice President, Biogen Idec 

Cocktails and Networking Reception 
 

BioPharma & Healthcare Brainstorming Session with a group of 30 Lok Sabha and Rajya Sabha Members of Parliament, India, Constitution Club, New Delhi December 4, 2009

Chaired by Honorable Srikant Jena, Minister of State for Chemicals & Fertilizers Opening Remarks- Karun Rishi, President, USA-India Chamber of Commerce Moderated by- Prof. Barry Bloom, Past Dean, Harvard School of Public Health
 

India Pharma Summit, Grand Hyatt Mumbai, India November 30, 2009

Organized by Department of Pharmaceuticals, Government of India in association with USA India Chamber of Commerce
Click here for program details

Business Roundtable and Post Summit follow up with Ashok Kumar Secretary to the Government of India, Department of Pharmaceuticals June 22, 2009 Harvard Faculty Club, Cambridge, Massachusetts

Opening remarks Prof. Barry R. Bloom, Harvard School of Public Health
Remarks Karun Rishi, President, USA-India Chamber of Commerce

Q&A and Open Discussion

Business Roundtable open to C level and senior executives from Healthcare, Pharma, Biotech, Medical Devices, Investment firms and Academia.

3rd annual BioPharma & Healthcare Summit Hyatt Regency Cambridge Massachusetts, USA May 14, 2009

Master of Ceremonies: Dr. Martin Mackay, President Global R&D, Pfizer
Opening Remarks: Karun Rishi, President-USA-India Chamber of Commerce

Release of USA-India Chamber of Commerce commissioned McKinsey & Company Position Paper by Dr. Martin Mackay, President Global R&D, Pfizer

Panel Discussion: Healthcare, Clinical Research and Industry-Academic Partnerships
Panelists :  Dr. Gerald Keusch, Associate Provost, BU School of Public Health, Dr. David Lacey, Senior Vice President & Head of Research, Amgen, Dr. Michael Rosenlatt, Dean Tufts University School of Medicine, Joe Smith, MD, PhD, Vice President-Emerging Technologies, Johnson & Johnson, Sridhar Mosur, Chief Executive Officer, Jubilant Biosys
Moderator: Dr. William Chin, Vice President - Discovery Research & Clinical Investigation, Eli Lilly & Company

Introduction by Manni Kanti Pudi, President, GVK BioSciences 

Keynote Address: Dr. Martin Mackay, President, Pfizer Global Research & Development

Panel Discussion: Funding Innovation, Cross Border Investment and M&A Trends
Panelists:  K.V.Subramaniam, President, Reliance Life Sciences; Jeff Collins, Executive in Residence, Pappas Ventures; Jeffrey Elton, Life Sciences Investor & Consultant; George Bickerstaff, Managing Director, CRT Investment Banking; Shrikumar Suryanarayan, Director General, ABLE
Moderator: Glen Giovanneti, Global Biotechnology Leader, Ernst & Young

Introduction: Banashri Bose Harrison, Minister (Commerce), Embassy of India

Keynote Address by Nobel Laureate Dr. Sidney Altman

Presentation by Department of Pharmaceuticals, Government of India. Paresh Johri, Deputy Secretary

Panel Discussion: Drug discovery, Development and Collaborative Research
Panelists:  Robert Armstrong, PhD, Vice President, Global External R&D, Eli Lilly; Venkat Jasti, Chairman & CEO, Suven Life Sciences; Ismail Kola, PhD, Senior Vice President- Discovery Research & Chief Scientific Officer, Schering-Plough; CSN Murthy, Chief Executive Officer, Aurigene Discovery; Dr. John Thompson, Vice President, Strategic Research Alliances, Vertex
Moderator: Ramesh Srinivasan, Principal, McKinsey and Company

Introduction: Reid Leonard, PhD, Executive Director, External Research & Licensing, Merck & Co.

Presentation of distinguished services award to Dr. Barry R. Bloom
Introduction by Dr. Gerald Keusch, Associate Provost, BU School of Public Health
Award Presentation by Dr. Martin Mackay and Karun Rishi

Address by Dr. Barry R. Bloom, Harvard University Distinguished Service Professor and Joan L. and Julius H. Jacobson Professor of Public Health at the Department of Immunology and Infectious Diseases, Harvard School of Public Health

Closing Remarks - James Mullen President & CEO, Biogen Idec 

Cocktails and Networking Reception

2nd annual BioPharma & Healthcare Summit Hyatt Regency Cambridge, Massachusetts, USA June 13, 2008

Inaugural BioPharma & Healthcare Summit May 7, 2007 Hotel Omni Parker House Boston, Massachusetts, USA

Welcome address: Karun Rishi, President, USA-India Chamber of Commerce
Opening remarks: James C. Mullen, Chairman Biotechnology Industry Organization (BIO), CEO & President, Biogen Idec

Release of USA-India Chamber of Commerce commissioned Ernst & Young Position Paper

Panel Discussion: Discovery, Development, IP & Regulatory Issues
Panelists: Dr. Alan Smith, Chief Scientific Officer, Genzyme; Dr. Peter Mueller, Chief Scientific Officer, Vertex Pharmaceuticals; Dr. Rashmi H.Barbhaiya, CEO and MD, Advinus Therapeutics; Dr. Sridhar Mosur, Managing Director, Jubilant Chemsys; Dr. Arun Chandavarkar, Chief Operating Officer, Biocon
Moderator: Dr. David C U'Prichard, Partner, Red Abbey Venture Partners and Care Capital

Keynote Address:
Dr. M.K.Bhan, Secretary to the Govt of India, Department of Biotechnology
Introduction to Dr. MK Bhan by Joel Marcus, Chairman, Alexandria Real Estate Equities

Panel Discussion: Investment Opportunities, Cross Border Investments, M&A Trends in US-India Life Sciences industry

Panelists: Dr. Helmut M. Schühsler, Managing Partner, TVM Capital; Dr. David Gluckman, MD & Head of European Life Sciences, Lazard; George Bickerstaff, Managing Director, CRT Capital Group; Hari Bhartia, Founder & Co-Chairman, Jubilant Bhartia Group; Dr. Stephen Knight, Managing Partner, Fidelity Biosciences
Moderator: Utkarsh Palnitkar , Partner-Transaction Advisory Services, Industry Leader - Health Sciences, Ernst & Young

Closing remarks: Dr. Helmut M. Schühsler, Managing Partner, TVM Capital and Board Member, USA-India Chamber of Commerce 

Cocktails & Networking Reception

India Healthcare Business Roundtable with Minister of Health, Harvard Faculty Club, Cambridge, Massachusetts, USA March 30, 2007

India Healthcare Business Roundtable with Dr. Anbumani Ramadoss, Honorable Union Minister of Health, Government of India and Prof. N.K. Ganguly, Director General, Indian Council of Medical Research (ICMR). 

Opening remarks: Prof. Barry R. Bloom, Dean, Harvard School of Public Health
Remarks: Karun Rishi, President, USA-India Chamber of Commerce
Q&A and open discussion

• Opportunities in the Indian Healthcare industry
• Opportunities in India for US Healthcare, Biotech, Pharma and Medical Device companies
• Public-Private partnership in Indian Healthcare

Business Roundtable open to C level and senior executives from Healthcare, Pharma, Biotech, Medical Devices, Investment firms and Academia.

 

   

India Business Summit, Maurya Sheraton, New Delhi, India January 23-25, 2007

Special focus on opportunities for US SME companies in India. The two day conference besides several keynotes will have sessions on IT, ITeS, Retail, Real Estate, Food Processing, Auto and Auto Components, Financing, Entrepreneurship, Policy, Market Access, Emerging sectors and Export opportunities. 

Senior policy makers and key executives from Walmart, Citigroup, Bank of America, SBA, Coca-Cola, Kelloggs, Tishman Spyer, Parsons, IBM, Hero Group, UPS, Bharti, General Motors, EXIM Bank, and Proctor & Gamble etc will participate in the panel discussions.

India Healthcare Business Roundtable, Harvard Club Boston, Massachusetts, USA December 6, 2006

Business Development Mission to India November 29 to December 5, 2006

USA-India Chamber of Commerce is pleased to support the Business Development Mission led by Amb. Franklin L. Lavin, Under Secretary for International Trade, U.S. Department of Commerce. This precedent-setting initiative, potentially involving the largest ever overseas delegation of its kind led by a U.S. Government official, will serve as the capstone of a year of successful activities conducted under the auspices of the U.S.-India Commercial Dialogue, honoring the commitment of President Bush and Indian Prime Minister Manmohan Singh to revitalize bilateral trade discussions. 

This is a great opportunity to get access to IndiaÂ’s high-level business, industry, and government representatives and opportunities to gain timely insights into the countryÂ’s trade and investment climate.

Business Roundtable with David Bohigian, Assistant Secretary, International Trade Administration, U.S. Department of Commerce, Fairmont Copley Plaza, Boston, Massachusetts, USA May 2, 2006

Program

Opening Remarks: Karun Rishi, President, USA-India Chamber of Commerce
Introduction: Nigel Thompson, Executive Director, Merck
Business Roundtable with David Bohigian, Assistant Secretary, U.S. Department of Commerce
Closing Remarks: Michael Fondo, Director, Fidelity Investments

Assistant Secretary BohigianÂ’s Market Access and Compliance (MAC) division identifies and overcomes trade barriers, resolves trade policy issues, and ensures that our trading partners fully meet their obligations under our trade agreements. MAC ensures access to world markets for American companies. 

MAC focuses on issues such as: Intellectual Property and Piracy, Quotas, Standards, Customs, Transparency and Contract Sanctity, National Treatment and Good Governance. 

This roundtable is only for senior executives.

Business Roundtable with Secretary, Department of Pharmaceuticals, Government of India, Boston, Massachusetts January 27, 2006

USA-India Chamber of Commerce and USIBC present an Executive Luncheon Business Roundtable with Satwant Reddy, Secretary to Government of India, Ministry of Chemicals. She is the top ranking official in the ministry. Her portfolio includes the regulation of all state-owned chemical companies, pharmaceuticals, and petrochemicals. Among other things, she is tasked responsibility for formulating India ’s data exclusivity and pharmaceutical price control policies.

Dinner meeting with Satwant Reddy, Secretary Department of Pharmaceuticals, Government of India, Boston, Massachusetts, January 26, 2006